XENON PHARMACEUTICALS INC. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- XENON PHARMACEUTICALS INC. stock issued during period, value, new issues for the quarter ending 2025-12-31 was $108.58M.
- XENON PHARMACEUTICALS INC. stock issued during period, value, new issues for the quarter ending 2025-09-30 was $2.36M.
- XENON PHARMACEUTICALS INC. stock issued during period, value, new issues for the quarter ending 2025-06-30 was $65.00K.
- XENON PHARMACEUTICALS INC. stock issued during period, value, new issues for the quarter ending 2025-03-31 was $1.15M.
- XENON PHARMACEUTICALS INC. stock issued during period, value, new issues for fiscal 2025 was $112.15M, a 828.17% increase from fiscal 2024.
- XENON PHARMACEUTICALS INC. stock issued during period, value, new issues for fiscal 2024 was $12.08M, a 96.58% decline from fiscal 2023.
- XENON PHARMACEUTICALS INC. stock issued during period, value, new issues for fiscal 2023 was $353.49M, a 27.26% increase from fiscal 2022.
- XENON PHARMACEUTICALS INC. stock issued during period, value, new issues for fiscal 2022 was $277.77M, a 37.90% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2025-12-31 | $108.58M derived: 10-K 12 month − 3 quarters · filed 2026-02-26 | $112.15M 10-K · filed 2026-02-26 |
| 2025-09-30 | $2.36M 10-Q · filed 2025-11-03 | |
| 2025-06-30 | $65.00K 10-Q · filed 2025-11-03 | |
| 2025-03-31 | $1.15M 10-Q · filed 2025-11-03 | |
| 2024-12-31 | $12.08M 10-K · filed 2026-02-26 | |
| 2023-12-31 | $353.49M 10-K · filed 2026-02-26 | |
| 2023-09-30 | $29.51M 10-Q · filed 2024-11-12 | |
| 2022-12-31 | $277.77M 10-K · filed 2025-02-27 | |
| 2022-06-30 | $269.89M 10-Q · filed 2023-11-08 | |
| 2022-03-31 | $7.88M 10-Q · filed 2023-11-08 | |
| 2021-12-31 | $447.28M 10-K · filed 2024-02-29 | |
| 2021-09-30 | $4.73M 10-Q · filed 2022-11-08 | |
| 2021-03-31 | $118.61M 10-Q · filed 2022-11-08 | |
| 2020-12-31 | $102.46M 10-K · filed 2023-03-01 | |
| 2020-03-31 | $102.46M 10-Q · filed 2021-11-10 | |
| 2019-12-31 | $27.40M 10-K · filed 2021-03-01 | |
| 2018-12-31 | $8.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-09 | $102.85M 10-K · filed 2020-03-09 |
| 2018-09-30 | $73.89M 10-Q · filed 2019-11-05 | |
| 2018-06-30 | $28.96M 10-Q · filed 2019-11-05 | |
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | $23.83M 10-K · filed 2018-03-07 |
| 2014-12-31 | $38.37M 10-K · filed 2017-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 |